Visual Abstract: Ipilimumab vs FOLFOX in ERBB2-Positive Esophagogastric Adenocarcinoma

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JUNE 23, 2022

Media advisory: The full study and commentary are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.2228?guestAccessKey=88a81f35-fbee-41a3-a7fc-574429ec2cf4&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=062322

 

Visual Abstract

Authors: Alexander Stein, M.D., of Hematology-Oncology Practice Eppendorf in Hamburg, Germany, is the corresponding author.

(doi:10.1001/jamaoncol.2022.2228)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.